

Participant Information Sheet/Consent Form

*Imperial College London
National Heart and Lung Institute
Translational and Experimental Medicine Building
Du Cane Road
London W12 0NN
Tel: +44 (0)20 7594 1100*

Participant Information Sheet/Consent Form

Imperial College London

Title: FOURIER LEGACY-Long term Study of LDL-c Lowering with Evolocumab: Observational Follow-up after the FOURIER OUTCOMES Study.

Short Title: FOURIER LEGACY

Protocol number: CTC0173

International Study Sponsor: University of Sydney

UK study coordinating centre: Imperial College London

1. Study Overview and Introduction

Thank you for your participation in the FOURIER study. As you may recall this study looked at whether treatment to lower cholesterol with Repatha (evolocumab) in people who had already experienced cardiovascular disease could reduce the risk of further cardiovascular events such as strokes and heart attacks. To do this, Repatha was compared with placebo (dummy injections) when added to existing statin treatment for an average treatment period of 26 months.

Patients were followed until November 2016 and the study found that Repatha reduced LDL ("bad") cholesterol by 59% and in doing so reduced the combination of heart attack, stroke, hospitalization for angina, coronary artery stenting or bypass surgery or cardiovascular death by 15%. We also saw a 27% reduction in the risk of having a heart attack and a 21% reduction in the risk of stroke. There was no increased risk of any important safety concerns with Repatha.

At the time of your last FOURIER study visit, your study doctor may have discussed the possibility of continued follow-up to see if there are any continuing benefits or any harms ("legacy" effects) of Repatha beyond the study period.

We would now like to invite you to take part in the FOURIER LEGACY study, an international investigator-initiated study being led by the University of Sydney located in Sydney, Australia and internationally coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre (CTC). The purpose of this study is to investigate the long term effects of Repatha on cardiovascular events.

If you decide to take part in this study, at each follow up time point, you will be asked to complete a short questionnaire about any new cardiovascular health events.

Your participation in this study is voluntary. If you decide not to take part, this will not affect your usual healthcare services that you would otherwise receive. Being in this study does not take the place of your regular medical care. If you decide to take part, but change your mind, you can

withdraw from the study at any time. Either way it will not affect the care you receive for your condition.

This form is called the Participant Information Sheet and Consent Form. It tells you about the study and explains what is involved for you and also tells you about any risks or benefits of taking part. Knowing what is involved will help you decide if you want to take part in this research study.

Please read this information sheet carefully. If you have any questions about the study or do not understand something in this form, ask the study doctor. You may talk about taking part in the study with anyone you choose. Do not sign this form unless your questions have been answered and you decide that you want to be part of this study.

If you decide you want to take part in the study, you will be asked to sign the Consent Form. No study procedures will be done until after you sign this form.

You will be given a copy of this Participant Information and Consent Form to keep.

2. What is the purpose of this study?

The purpose of this study is to find out whether treatment with Repatha during the FOURIER study may provide longer lasting protection against future cardiovascular events. We hope to follow participants for up to 5 years after the end of the FOURIER study.

We plan to follow 10,000 patients who took part in the FOURIER study and to enrol 1000 participants from the study in the UK.

3. What does participation in this research involve?

You will be contacted by telephone or post by your original FOURIER OUTCOMES study doctor, who will explain the FOURIER LEGACY study and ask whether you wish to take part.

If you are willing to take part, you will be asked if you are willing to be contacted by a National Coordinating Centre (NCC), which for the UK is Imperial College. Your doctor (from the previous FOURIER study) will then send your contact details to the NCC and all further contact for the FOURIER LEGACY study will be done by the NCC on behalf of your doctor. You will be asked to sign the Consent Form, and confirm your preferred method of communication (SMS, email, mail or phone). We will ask you to give your permission for the NCC to access your medical records and to contact your caregivers about hospitalisations or other events during the follow-up period. We will also ask you to provide contact details for next of kin and other relatives/friends as well as your General Practitioner. If we are unable to contact you, we would first contact your GP to check your health status and may subsequently contact your next of kin/other contacts in case your own contact details have changed.

Following your consent you will be contacted again in 6 months, and then again annually until 5 years after the end of the FOURIER study (i.e. around the end of 2021), via your preferred method of communication. You will be directed to a secure website and asked to complete a short questionnaire about any cardiovascular events (heart attack, stroke, angina, any hospitalisations for heart related reasons), and to provide details of any lipid lowering medications. If you are not sure of the answers, or have any questions you can request help via the website and the NCC team will contact you. *If you prefer not to complete the online process, we can do everything by telephone.*

If you develop problems with your memory during the study, such that it would be difficult for you to answer your questionnaires, we would ask that you, your next of kin, or your GP contacts the study team. We would not continue to contact you for information if this happens.

Study costs

There are no additional costs associated with taking part in this study, nor will you be paid.

4. What else do I have to do?

There are no restrictions on your medications or treatments during this study. Your medical care will continue to be managed by your usual treating clinicians.

5. Do I have to take part in this research study and what are the alternatives to taking part?

Taking part in any study is voluntary. If you do not wish to take part, you do not have to. If you decide to take part and later change your mind, you are free to withdraw from the study at any stage. Your decision on whether or not to take part, or to take part and then withdraw, will not affect your routine treatment, your relationship with those treating you or your relationship with Imperial College London.

6. What are the possible benefits of taking part?

There will not be any direct benefit to you by taking part in this study as you will not be receiving any study treatment. Your taking part may give more scientific information about the long-term effects of Repatha and may benefit other patients in the future, if Repatha is found to prevent further cardiovascular events.

7. What are the possible risks and disadvantages of taking part?

We do not anticipate any risks to you from taking part in this study as you will not be receiving any study treatment. If you experience any serious reactions that you feel may be related to the study drug you took in the previous FOURIER study or current use of Repatha, please talk to the NCC team (Imperial College).

8. What if new information arises during this study?

Sometimes during the course of a study, new information becomes available about the treatment that is being studied. If this happens, the NCC will tell you about it and discuss it with you. New information will also be posted on the study website <http://www.imperial.ac.uk/medicine/fourier-legacy>

9. What if you want to stop being in the study?

If you decide that you no longer want to take part in any aspect of the study, please call the NCC to let us know. You do not have to give a reason.

If you or your family feel that you are no longer able to take part because of any health-related or other reasons, please also let us know, so that we can withdraw you from the study as necessary.

We may ask, with your permission, if we can contact your GP or continue to use your medical records, to follow your health and well-being. You do not have to agree to this if you do not wish to.

If you decline all follow-up, no further study-related contacts or information collection will occur.

Any information already collected before your study withdrawal will be used in the study analysis, where allowed by local law. This will help to maintain the reliability of the study. Other authorized parties, including the NCC, its consultants, contractors, and agents may also use the data. Data collected up to the time you withdraw consent will form part of the study results.

10. Could this study be stopped unexpectedly?

This study may be stopped unexpectedly for a variety of reasons. These may include decisions made by local health authorities, or the study sponsor (University of Sydney).

11. What happens when the study ends?

Once the study ends, the NCC will no longer contact you.

Once the study results are known, a written plain-English summary of the results of the study will be shared for the NCC to discuss with you. A summary of the results will also be published on the NHMRC Clinical Trials Centre website (www.ctc.usyd.edu.au), search for 'trial results'. Public information is provided in such a way that you cannot be identified.

This summary will also be available on the Imperial College study website (<http://www.imperial.ac.uk/medicine/fourier-legacy>)

12. What will happen to information about me?

By signing the Consent Form you consent to your study doctor and relevant study staff at the NCC (Imperial College) collecting and using personal information about you for the study. The research team at Imperial College will keep your name, NHS number and contact details confidential and will not pass this information to the Sponsor organisation. The research team at Imperial College will use this information as needed, to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study.

The University of Sydney will only receive information without any identifying information. This information will be collected in a study database and will be identified by a code number. Only your study doctor and the study team at Imperial College will be able to link the code number to you personally. The people who analysis the information will not be able to identify you and will not be able to find out your name or date of birth. Your information will only be used for the purpose of this study and it will only be disclosed with your permission, except as required by law.

The University of Sydney will be acting as data controller for the study (which means that they take responsibility for looking after your information and using it properly) and Imperial College will be a data processor.

Information about your participation in this study may be recorded in your health records. Information about you may be obtained from your health records for the purpose of this study. By signing the Consent Form you agree to the study team accessing health records if they are relevant to your participation in this study.

Your study information, identified only by your FOURIER study number, will be held electronically in a secure study database by the NHMRC Clinical Trials Centre in Sydney, Australia. The data from this study will be kept for at least 15 years from the end of the study, after which it will be securely destroyed.

The results of this study and a copy of the anonymised database will be provided to the TIMI Study group for the purposes of research analysis. This data may also be provided to Amgen Inc. for further analyses and reporting to health regulatory authorities in the UK and other countries.

Your health records and any information obtained during the study are subject to inspection (to check the accuracy of the data) by the relevant authorities and authorised representatives of the Global Sponsor (University of Sydney), Imperial College, funder (Amgen), the Medicines and Healthcare Products Regulatory Authority (MHRA), European Medicines Authority (EMA), Human Research Ethics Committee (HREC) and other relevant regulatory authorities, or as required by law. By signing the Consent Form, you authorise release of, or access to, this confidential information to the relevant study personnel and regulatory authorities as noted above.

It is anticipated that the results of this study will be published and/or presented at professional meetings. In any publication and/or presentation, information will be provided in such a way that you cannot be identified.

The results of this study will be provided to Amgen Inc. for reporting to health regulatory authorities in the UK and other countries.

In accordance with relevant data protection legislation, you have the right to request access to your information collected and stored by the study team. You also have the right to request that any information with which you disagree be corrected..

Please contact the study team member named at the end of this form if you would like to access, correct or erase your information, or email the study team at fourier.legacy@imperial.ac.uk. You can find out more about how we use your information at www.hra.nhs.uk/information-about-patients/

13. Electronic health records

We would also like to collect information about your ongoing health status from NHS records if you give permission to do so and will be asking for your consent to allow us to request this

information. We will be applying to NHS-Digital for this information via the DARS (data access request) system.

If permitted (and if you have consented), we would send some personal details about yourself to NHS Digital. This would include your name, date of birth, NHS number and FOURIER ID. NHS digital would then link these details with some of your records- hospital admissions, critical care admissions, diabetes register and civil registration data (in case of death).

NHS-Digital would then send us this information, in which you would be identified only by your FOURIER ID.

Imperial College would be the data controller for this part of the study and access to this data would be only allowed to certain named members of the study team. Your data would be kept securely within an approved 'secure IT enclave' within Imperial College.

You have the right to request that no further information from NHS Digital is gathered about you - if you wish to do this, please contact the study team on 0207 594 1100 or email fourierlegacy@imperial.ac.uk.

14. Complaints and compensation

If you have any concerns or other questions about this study or the way it has been carried out, you should contact your study doctor Dr Judith Mackay on 0207 594 1100 or you may contact the Patient Advice and Liaison Service (PALS) on 0203 312 7777 or email fourier.legacy@imperial.ac.uk.

Any complaints will be assessed on a case by case basis and will be dealt with by the relevant regulatory authorities as required.

15. Who is organising and funding the study?

This is an international investigator-initiated study being led by the University of Sydney, Australia and conducted in the UK by Imperial College, London. In Europe and South Africa, the study is being managed by Imperial College London.

This study is sponsored by the University of Sydney and is fully funded by Amgen Inc.. Amgen Inc. may benefit financially from this study if, for example, the study assists the company to obtain additional approvals for Repatha.

Imperial College will receive a payment from NHMRC, Sydney, for undertaking this study. No member of the study team will receive a personal financial benefit from your involvement in this study (other than their ordinary wages).

16. Who has reviewed the study?

This study will be carried out in accordance with the recommendations for physicians involved in research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 and later revisions.

All research in the UK is looked at by an independent group of people called a Research Ethics Committee (REC). This study has been approved and given favourable opinion by the WALES REC 6. Any person with concerns or complaints about the conduct of this study should contact the the Imperial College Healthcare NHS Trust R&D Research Governance Officer on 0207 594 1872 or the WALES REC 6 Manager on 01267 61 1164 and quote protocol number CTC 0173.

17. Further information and who to contact

If you want any further information concerning this study or if you have any medical problems which may be related to your involvement in the study (for example, any side effects), you can email fourier.legacy@imperial.ac.uk or telephone the principal study doctor on +44 (0)20 7594 1100 or any of the following people:

NCC contact person

Name	Dr Judith Mackay	Candida Coghlan
Position	Principal Investigator	Clinical Research Associate
Telephone	020 7594 1100	0207 594 1100

Consent Form Imperial College, London.

Title	FOURIER LEGACY-Long term Study of LDL-c Lowering with Evolocumab: Observational Follow-up after the FOURIER Outcomes Study
Short Title	FOURIER follow-up study
Protocol Number	CTC 0173
Study Sponsor	University of Sydney
Coordinating Centre	Imperial College London
Coordinating Principal Investigator/ Principal Investigator	Dr Judith Mackay

Declaration by Participant (please put your initials in each box)

- I confirm that I have read the Participant Information Sheet (v2.1 07.11.19 (corrected)) for the above study. I have had the opportunity to consider the information and ask questions and I have received satisfactory answers. ☐
- I understand the purposes, procedures and risks of the study described in the study. ☐
- I freely agree to take part in this study as described and understand that I am free to withdraw at any time during the study without affecting my future health care. ☐
- I give permission for my GP, other health professionals, hospitals or laboratories outside this hospital to release information to Imperial College concerning my disease and treatment for the purposes of this study. I understand that such information will remain confidential. ☐
- I understand that, if I decide to discontinue the study, the study team may request my permission to obtain access to my medical records for collection of follow-up information for the purposes of research and analysis. ☐
- I understand that my medical records may be looked at by representatives of the Sponsor, Amgen, NHS Trusts, and regulatory authorities. I give permission for these individuals, who are obliged to keep my information confidential, to have access to my records. ☐
- I authorise the study team at Imperial College London to access my health information and receive copies of any relevant material about my health during the course of the study ☐
- I understand that information concerning my health will be transferred to the University of Sydney but that this will be identified by my FOURIER ID only and the University of Sydney will not have access to any of my confidential information. ☐
- I authorise the study team at Imperial College to provide information to NHS Digital and to receive health care information from NHS Digital identified only by my FOURIER ID. I understand that this information will be kept at Imperial College and not shared with any other parties. ☐
- I agree to take part in the above study ☐

FOURIER Participant ID _____

Name of Participant (please
print first name and last name
in full) _____

Signature _____ Date _____

Declaration by Study Doctor/Senior Researcher[†]

I believe that the participant has understood the study, its procedures and risks.

Name of Study Doctor/

Senior Researcher[†] (please print) _____

Signature _____ Date _____

[†] A senior member of the research team must provide the explanation of, and information concerning, the study.

Note: All parties signing the consent section must date their own signature.

One original copy of the signed consent form will be sent to the participant, one original copy will be filed in the Investigator Site File